We will be delighted if you decide to call by our booth    -  Booth # 4062

Alternatively please contact    deirdre.barry@biosensia.com

to make an appointment to meet with a representative of the company.

Dublin, Tuesday 19 February 2013 … Biosensia Ltd., a point of care diagnostics company, today announces the appointment of James D. Merselis as Chief Executive Officer. Jim joins as the company seeks to secure regulatory approval for RapiPlex, its Point of Care platform, and continues to progress a pipeline of commercial deals.

Jim joined Biosensia in 2012 as a non-executive director, and will work closely with outgoing CEO Diarmuid Flavin to manage the transition. He is a non-executive director at Trinity Biotech (NASDAQ: TRIB) and has been a consultant to a range of healthcare companies. Jim was formerly President and CEO of ITC Nexus Dx, Inc, a privately held diagnostics company working to improve patient care by providing rapid and reliable point-of-care medical test information. Prior to this, he served as President and CEO of Alverix, Inc, a privately held company developing portable medical diagnostic instruments.

Previous roles included, President and CEO of Hemosense Inc. (AMEX:HEM) (now Alere), President and CEO of Micronics (now SONY), and a number of positions with Boehringer Mannheim Diagnostics (now Roche Diagnostics).

Mr. Merselis said, “This is a great time to be joining Biosensia. RapiPlex is a fantastic platform, and will make a significant impact in the point of care or near patient testing market and other industries where sensitive information is needed in decentralized locations. With the initial product development now largely completed, we will be securing regulatory approval prior to product launch.”

Dr Jim Walsh, Chairman of Biosensia ltd., said: “We are very pleased to have Jim on board. He brings a wealth of experience in healthcare diagnostics and in particular the point of care space. This experience will be crucial as Biosensia continues to develop and RapiPlex reaches commercialisation.”

Over the past eighteen months, Biosensia has achieved a number of important milestones. The company raised €2 million in November 2011, and July 2012 saw the company showcase the RapiPlex platform for the first time at the American Association of Clinical Chemistry (AACC) conference held in California. In addition, the company has registered its first patent, and is currently completing a new round of investment.

-ends-

For further information, please contact:

Tony Stephenson

PR Consultant

Tel: +44 (0)7899 796655

Email: anthonytstephenson@gmail.com

About Biosensia

Biosensia is development stage in vitro diagnostics company, focused on next generation point of care (POC) technology with a broad range of applications. Biosensia has developed RapiPlex®, a rapid, novel, multiplexing in vitro diagnostics platform, which is suitable for use in all immunoassay formats and for multiple applications including medical, environmental, food safety and security. Biosensia is an independent, venture capital funded company based in the Nova UCD incubation centre at University College Dublin, Ireland.

www.biosensia.com

Spotlight on Point-of-Care Testing

Innovation, Expansion Evident at AACC Clinical Lab Expo in Los Angeles
By Bill Malone

This year, more than 120 companies came to Los Angeles to showcase POC products at the AACC Clinical Lab Expo, and the buzz about POC spilled over into sessions at the AACC Annual Meeting. Speakers covered many POC topics, including the explosion of technology and where future opportunities lie.

http://www.aacc.org/publications/cln/2012/october/Pages/POCT.aspx#

Please note you may need to log in/register to read the article.   This link is published with permission of AACC, Washington, D.C.  This material is copyright protected.

09 January 2013

Silicon Republic Showcases Biosensia’s Point of Care Technology Platform

Dublin, Ireland, 09 January 2013 … Silicon Republic, Ireland’s Number One source for technology news has showcased Biosensia’s leading point of care diagnostic platform, RapliPlex.

The article describes how RapiPlex works, and its benefits for healthcare, particularly in a primary care setting. Diarmuid Flavin, CEO of Biosensia, explains: “Point of care is the ability to be able to perform what are traditionally complex immunoassays in a decentralised fashion.  At the moment if you present yourself at a GP’s office for a blood test, what typically happens is that blood is taken in several tubes and sent to a central laboratory for testing”. “Our technology allows for the same test to be performed in the Doctor’s surgery.  The patient will receive the result for the ailment being tested for then and there, during that visit.”

The article also looks at the market opportunity provided by RapiPlex. “Our platform technology lends itself to multiplex analysis,” adds Flavin. “The advantage of what we have done is that we have one reader and you can have multiple different products off that reader - each cartridge can provide as little as one analyte result or as many as 12 or any combination thereof. “There are a whole host of emerging biomarkers coming to the fore now, such as for kidney and liver damage and cardiovascular risk profiling.  We are actively seeking and have are having discussions with collaboration partners around new content for the platforms.”

The article also discusses he future plans with Flavin for Biosensia:  “We are about to receive our first CE mark, which we expect to have in early 2013, we will also submit our first product for US 510k approval at the same time.”

The initial approval for the RapiPlex platform is using a myoglobin assay, and Biosensia plans to develop more products, including tests for screening sexually transmitted diseases, with Flavin foreseeing a “significant growth phase” in the next 18 months as Biosensia ramps up manufacturing.

Irish startup Biosensia will bring its RapiPlex point-of-care (POC) IVD Platform technology to the 2012 AACC Annual Meeting in the hopes of finding some eligible suitors.  The system combines ease of use with rapid, cost-effective deployment in almost any environment.  The company hopes to have the technology on the market in the United States by the first quarter of 2012.  IVD Technology had a chat with the CEO Diarmuid Flavin as he was getting ready to head to Los Angeles to exhibit at the AACC event.

Read what Diarmuid has to say  IVD Technology

Dublin, 13 November 2012 … Biosensia Ltd., a point of care diagnostics Company, announced it will participate in MEDICA trade fair 2012 to be held November 14-17, 2012 in Dusseldorf, Germany

Diarmuid Flavin, CEO of Biosensia Ltd., said: “We are delighted to be participating at Medica this year.  Medica continues to be an important trade fair for diagnostic medical devices and Biosensia hopes to further our commercialization plans While exhibiting at the show.”

Over the past year, Biosensia has hit a number of important milestones. The company raised €1.2 million in November 2011, and July 2012 saw the company showcase the RapiPlex platform for the first time at the AACC annual meeting.

Biosensia takes part in Ireland Trade Mission to Japan

Dublin, 31 October 2012 … Biosensia Ltd., a point of care diagnostics Company, is taking part in a week-long Enterprise Ireland Life Sciences and Functional Foods trade mission to Japan.

Biosensia has joined fourteen of Ireland’s leading and most innovative life science and food companies as they develop new business opportunities in one of the world’s biggest markets. Japan has the world’s second largest pharmaceutical and medical devices market in the world, valued at $96 billion in 2010.

Diarmuid Flavin, CEO of Biosensia Ltd., said: “I am delighted to be part of this important trade mission to Japan.  Biosensia’s RapiPlex Technology was designed with the global market place in mind and we believe there is significant opportunity to be found in the Japanese market.”

The Minister for Research and Innovation, Mr. Sean Sherlock said: “Supporting indigenous businesses to grow and export is central to the Government’s plans for recovery, growth and jobs. The objective of this trade mission is to continue delivering on these plans by highlighting Ireland’s capabilities in food innovation and life sciences technology. These two sectors are increasingly important in terms of Irish exports to Japan and offer significant potential for further growth in Japan.

Over the past year, Biosensia has hit a number of important milestones. The company raised €1.2 million in November 2011, and July 2012 saw the company showcase the RapiPlex platform for the first time at the AACC annual meeting.

-ends-

For further information, please contact:

Tony Stephenson

PR Consultant

Tel: +44 (0)7899 796655

Email: anthonytstephenson@gmail.com

About Biosensia

Biosensia is an in vitro diagnostics company, focused on developing next generation point of care (POC) technology with a broad range of applications. Biosensia has developed RapiPlex, a rapid, novel, multiplexing POC in vitro diagnostics platform, which can be used for a wide range of diagnostic applications. RapiPlex is suitable for use in all immunoassay formats and for multiple POC applications including medical, environmental, food safety and security. RapiPlex is suitable for use with a variety of small and large sample sizes and types including whole blood, serum, plasma, saliva and urine. Biosensia collaborates with healthcare companies to develop point of care diagnostics products. Biosensia is an independent, venture capital funded company based at NovaUCD, the Centre for New Ventures and Entrepreneurs at University College Dublin, Ireland.

www.biosensia.com

23 October 2012

Biosensia appoints James D. Merselis as Non-Executive Director

Dublin, 23 October 2012 … Biosensia ltd., a point of care diagnostics Company, today announces the appointment of James D. Merselis as Non-Executive Director.

Jim is currently a non-executive director at Trinity Biotech (NASDAQ: TRIB) and a consultant to healthcare diagnostics companies. He was formerly President and CEO of ITC Nexus Dx, Inc, a privately held diagnostics company working to improve patient care by providing rapid and reliable Point-of-Care medical test information. Prior to this, he served as President and CEO of Alverix, Inc, a privately held company developing portable medical diagnostic instruments.

Previous roles included, President and CEO of HemoSense Inc, (AMEX: HEM), President and CEO of Micronics, and a number of positions with Boehringer Mannheim Diagnostics (now Roche Diagnostics).

Diarmuid Flavin, CEO of Biosensia ltd., said: “Jim will make an excellent addition to the board at Biosensia. He has a wealth of experience in the diagnostics and point of care in particular and as we progress towards the commercialization of RapiPlex, his skills and experience will be invaluable.”

Jim Merselis added: “I am very pleased to be joining Biosensia at this exciting time. The company has developed an excellent product with RapiPlex, and I look forward to helping steer the company to success in the point of care market.”

Over the past year, Biosensia has hit a number of important milestones. The company raised €1.2 million in November 2011, and July 2012 saw the company showcase the RapiPlex platform for the first time at the AACC annual meeting.

-ends-

For further information, please contact:

Tony Stephenson

PR Consultant

Tel: +44 (0)7899 796655

Email: anthonytstephenson@gmail.com

About Biosensia

Biosensia is an in vitro diagnostics company, focused on developing next generation point of care (POC) technology with a broad range of applications. Biosensia has developed RapiPlex, a rapid, novel, multiplexing POC in vitro diagnostics platform, which can be used for a wide range of diagnostic applications. RapiPlex is suitable for use in all immunoassay formats and for multiple POC applications including medical, environmental, food safety and security. RapiPlex is suitable for use with a variety of small and large sample sizes and types including whole blood, serum, plasma, saliva and urine. Biosensia collaborates with healthcare companies to develop point of care diagnostics products. Biosensia is an independent, venture capital funded company based in the Nova UCD incubation centre at University College Dublin, Ireland.

www.biosensia.com

October 2^nd 2012

Biosensia’s CEO Diarmuid Flavin to present ‘RapiPlex’ point of care platform at the Advamed 2012 Medtech conference in Boston.

Biosensia will be presenting at the Advamed Medtech Conference at the Boston Convention and Exhibition Centre, October 2^nd & 3^rd 2012.

Biosensia Ltd., a point of care diagnostics Company, will be demonstrating RapiPlex, its point of care diagnostics platform.  Headquartered in Nova, University College Dublin, Ireland, Biosensia is poised to become a major player in the development of next-generation, point of care diagnostics.

RapiPlex, is a novel, user-friendly, cost effective, multiplexing point of care in vitro diagnostics platform that gives access to a broad range of diagnostic applications including acute phase diagnostics, prognostic diagnostic panels and companion diagnostics at the point of care. RapiPlex enables the transition of complex immunoassays from the central laboratory to the point of care across a wide variety of samples types.

Diarmuid Flavin, CEO, is delighted to be presenting at Advamed.  According to Diarmuid “Since Biosensia began commercializing its ‘RapiPlex’ platform we’ve seen substantive market demand across a range of diagnostic applications.  Our selection to present at Advamed is a great opportunity for Biosensia as it will afford customers and investors the opportunity to learn more about our company, our technology, and the solutions we offer”.

Dublin, 16 April 2012 … Biosensia Ltd., a point of care diagnostics Company, will be presenting two posters at this year’s AACC Oak Ridge Conference, ‘Emerging Technologies for 21st Century Clinical Diagnostics’, in San Jose.  The posters will illustrate a series of developments proving the effectiveness of Biosensia’s RapiPlex platform.

RapiPlex, is a novel, user-friendly, cost effective, multiplexing point of care in vitro diagnostics platform that gives access to a broad range of diagnostic applications including acute phase diagnostics, prognostic diagnostic panels and companion diagnostics at the point of care. RapiPlex enables the transition of complex immunoassays from the central laboratory to the point of care across a wide variety of samples types.

The posters: ‘Evaluation of a Multiplex Drugs of Abuse Detection Platform with Integrated Sample Handling Technologies’ and ‘RapiPlex a small volume whole blood quantitative microfluidic fluorescent Point of Care platform’ will describe how Biosensia’s RapiPlex platform can be used to detect drugs of abuse; making it suitable for use in a variety of point of care settings such as hospital ER, doctor’s office, or workplace testing. The ability to detect cardiac markers in blood demonstrates how RapiPlex can be used to rapidly diagnose heart attacks in a clinical setting.

Niamh O’Luanaigh, Head of Assay Development at Biosensia, who led the work and is presenting the posters at the conference said: “The posters show just how powerful RapiPlex is and the significant range of uses for it. We believe that RapiPlex can have a significant impact on the way we currently do test, supporting acute phase diagnostics, prognostic diagnostic panels and companion diagnostics at the point of care.”

Diarmuid Flavin, CEO of Biosensia Ltd., said: “This scientific validation of RapiPlex is an important step for us. Having secured funding last year, we are now ready to begin the 510k process for US approval and secure a CE mark for Europe, before moving to full commercialisation in 2013.”

The Oak Ridge Conference is the American Association for Clinical Chemistry’s annual forum for emerging clinical diagnostic technologies and brings together thought leaders from industry, academia, and clinical laboratories. The conference focuses exclusively on pre-commercial technologies.